NCT00095641撤回2 期
S0225: Phase II Study of Adjuvant Low-Dose Capecitabine After Salvage Surgery in Patients With Locally Recurrent or Persistent Squamous Cell Carcinoma of the Head and Neck
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving capecitabine after surgery may kill any remaining tumor cells.
PURPOSE: This phase II trial is studying how well capecitabine works in treating patients who have undergone surgery for locally recurrent or persistenthead and neck cancer.
详细描述
OBJECTIVES:
- Determine 2-year disease-free survival of patients treated with surgical salvage followed by adjuvant low-dose capecitabine for locally recurrent or persistent squamous cell carcinoma of the head and neck .
- Determine the toxic effects of this drug in these patients.
- Determine 2-year overall survival of patients treated with this drug.
- Determine patterns of disease relapse in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine once daily for 12 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed squamous cell carcinoma of the head and neck
- •Locoregionally recurrent or persistent disease
- •No thyroid gland, salivary gland, or nasopharynx disease sites
- •Must have undergone definitive or post-operative radiotherapy at the time of initial curative treatment
- •Must have undergone salvage surgical resection within the past 56 days
- •All current disease must be completely resected, including resection of recurrent primary disease and/or neck dissection, if regional nodal disease is present
- •Surgical margins must be free of disease on final pathological evaluation of specimens
- •No definitive or adjuvant radiotherapy or reirradiation for recurrent or persistent disease allowed at the time of salvage treatment
- •No evidence of distant disease by clinical examination and CT scan of the chest and upper abdomen (including the liver) within the past 90 days
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Zubrod 0-1
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Not specified
- •Creatinine clearance ≥ 30 mL/min
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •Able to take oral tablets OR able to take crushed tablets through a gastrostomy tube
- •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •No concurrent biologic therapy
- •No concurrent filgrastim (G-CSF)
- •Chemotherapy
- •Prior systemic chemotherapy as definitive therapy for head and neck cancer allowed (prior treatment with fluorouracil allowed, but must be catalogued)
- •More than 5 years since prior systemic chemotherapy for any other cancer diagnosis
- •No other concurrent chemotherapy
- •Endocrine therapy
- •No concurrent anticancer hormonal therapy
- •Concurrent hormonal therapy for non-cancer diagnosis allowed
- •Radiotherapy
- •See Disease Characteristics
- •No concurrent radiotherapy
- •See Disease Characteristics
- •Recovered from prior surgery
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract CancerExtrahepatic Bile Duct CancerGallbladder CancerLiver CancerNCT00363584University Hospital Southampton NHS Foundation Trust360
已完成
2 期
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaStage IV Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityHead and Neck CancerStage IV Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Verrucous Carcinoma of the Oral CavityNCT01044433Abramson Cancer Center at Penn Medicine44
已完成
1 期
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic CancerPeriampullary AdenocarcinomaPancreatic CancerNCT00983268Vanderbilt-Ingram Cancer Center21
已完成
2 期
Capecitabine in Treating Patients With Metastatic Breast CancerBreast CancerNCT00274768Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins26
已完成
2 期
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or ChemoHead and Neck CancerNCT00258310Barbara Ann Karmanos Cancer Institute35